Navigation Links
Surveyed Oncologists Expect to Prescribe Provenge to about Half of Their Prostate Cancer Patients if the Vaccine is Approved

WALTHAM, Mass., July 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, if Dendreon's Provenge receives regulatory approval, surveyed oncologists expect to prescribe Provenge to 54 percent of patients with asymptomatic hormone refractory metastatic prostate cancer. Due to the side effects associated with currently available chemotherapy, most oncologists recommend that men who have stopped responding to hormone therapy wait for the development of symptoms before starting chemotherapy.

The new Physician & Payer Forum report entitled Clinician and Payer Attitudes Toward Emerging Cancer Vaccines for Prostate Cancer, Lung Cancer, and Glioma finds that clinicians are willing to prescribe Provenge to patients in the absence of symptoms. The report also finds that three-quarters of surveyed oncologists and urologists consider Provenge a major breakthrough in the treatment of prostate cancer. Additionally, 89 percent of surveyed urologists expect to prescribe Provenge for prostate cancer.

"Treatment rates for advanced prostate cancer will be boosted by an effective vaccine which also carries a benign side effect profile," said Decision Resources Analyst Marcus Hoyle. "Surveyed clinicians indicate they are very encouraged by the fact that, in a Phase III clinical trial, Provenge demonstrated an improvement in median overall survival in prostate cancer patients."

In addition to Provenge, other therapeutic vaccines in development for cancer include Merck KGaA's Stimuvax for non-small-cell lung cancer and Celldex Therapeutics/Pfizer's CDX-110 for glioblastoma multiforme (glioma). Surveyed experts consider both drugs to be the most promising therapeutic vaccines for the treatment of these two diseases, owing to an impressive effect on overall survival in Phase II clinical trials.

Therapeutic cancer vaccines are likely to command a high price. Although most surveyed clinicians expect to prescribe these agents, a minority of surveyed managed care organizations' (MCO) pharmacy directors expect to place Provenge, Stimuvax and CDX-110 on the top two tiers of their formularies. Only 25 percent of surveyed MCOs expect to place Provenge on tier one or tier two of their formularies, assuming the vaccine is priced in line with Roche/Chugai's Avastin. Additionally, of surveyed MCOs, 30 percent expect to place Stimuvax on the top two tiers of their formularies and 35 percent expect to place CDX-110 on the top two tiers of their formularies.

Clinician and Payer Attitudes Toward Emerging Cancer Vaccines for Prostate Cancer, Lung Cancer, and Glioma is based on a U.S. survey of 70 oncologists, 71 urologists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                              Decision Resources, Inc.
    Christopher Comfort                             Elizabeth Marshall
    781-296-2597                                    781-296-2563               

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibbs Orencia
2. For Treatment of Type 2 Diabetes, 89 Percent of Surveyed Endocrinologists Identify a Need for Additional GLP-1 Analogues and 71 Percent Say the Same About DPP-IV Inhibitors
3. For Treatment of Dyslipidemia, Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials
4. Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting
5. Surveyed Psychiatrists and PCPs Expect to Increase Their First-Line Use of SNRIs Over the Next Two Years for the Treatment of Generalized Anxiety Disorder
6. For Alzheimers Disease, Surveyed Neurologists Identify a Therapys Effect on Cognitive Decline as the Attribute That Most Influences Their Prescribing Decisions
7. For Bipolar Depression, Surveyed Experts Indicate That Current and Emerging Therapies Have No Advantage Over Seroquel in Decreasing the Severity of Symptoms
8. Surveyed Experts Indicate That the Combination of Sutent and Taxol Has Advantages Over the Combination of Avastin and Taxol in the Treatment of Metastatic Triple-Negative Breast Cancer
9. Surveyed Specialists Foresee Greater Use of Parenteral Outpatient Therapy for the Treatment of Osteomyelitis
10. For Atrial Fibrillation, Surveyed Experts Indicate That Multaq, Celivarone and ATI-2042 Have Advantages Over Propafenone in the Maintenance of Normal Sinus Rhythm
11. For Ulcerative Colitis, Surveyed Experts Indicate That Corticosteroids Have Advantages Over Remicade in the Induction of Remission
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Brenntag ... exclusive channel partner for the Nutraceutical Specialties products into oral solid dosage in ... immediately. , “We are pleased to announce our expanded distribution agreement with ...
(Date:11/30/2015)... ... November 30, 2015 , ... An inventor from Charlottesville, Va., is concerned ... last baby had high blood pressure due to loud noises," she said, "so I ... from noise pollution as well as radio waves and microwaves." , The baby BABY ...
(Date:11/30/2015)... ... November 30, 2015 , ... Since its inception, ... in independent living, assisted living and all other retirement options. Support for issues ... and research remains a top priority. , So it’s no surprise that ...
(Date:11/30/2015)... ... November 30, 2015 , ... Sikka Software announced today that they ... Ecosystem empowers dentists to make complex business decisions by providing the tools and information ... free fee survey with 10 procedures customized by zip code. , The Sikka ...
(Date:11/30/2015)... ... November 30, 2015 , ... Healthjump, Inc. announced ... a Healthcare IT consulting, development and support company. The purchase will expand the ... within DataTrade to extend the services currently provided by Healthjump. , ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 2015   Royal Philips (NYSE: PHG ... first MRI guided user interface and automatic scan parameter ... MR Conditional implants, such as knee and hip replacements, ... Society of North America Annual Meeting (RSNA) . The ... confidence of this growing patient population. ScanWise Implant adds ...
(Date:11/30/2015)... PUNE, India , November 30, 2015 ... in 2014, and is expected to grow at a CAGR of ... was valued at USD 135.6 million in 2014, and ... to 2020. --> According to the new Market Research ... Minimally invasive, non-invasive), By End User (Hospitals, ambulatory care, others) - ...
(Date:11/30/2015)... the Six Months Ended 30 September 2015 2014RestatedChange%Turnover 545,575 , 518,852 ... , 384,242 , 9.8 Hospital Management ... , (18.3) Medical Insurance Administration Service Income , ... Medical Devices and Accessories Sales , 89,645 , ... 2,822 , 2,917 , (3.3) ...
Breaking Medicine Technology: